Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024

Conditions
Blood Protein Disorders, COVID-19, COVID-19 Infection, +30 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Johns Hopkins University Baltimore, Maryland, United States
  • U Mass Chan Medical School Worcester, Massachusetts, United States
  • SUNY-Stony Brook Stony Brook, New York, United States
View Trial Details
Active, Not Recruiting

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

NCT05396885

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • HonorHealth Cancer Transplant Institute Scottsdale, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

NCT04221178

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
View Trial Details
Active, Not Recruiting

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

NCT06939283

Conditions
Advanced or Metastatic Solid Tumors, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • Emory Winship Cancer Institute Atlanta, Georgia, United States
  • Northwestern University Chicago, Illinois, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
View Trial Details
Active, Not Recruiting

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Alfred Hospital Melbourne, Australia
  • University Hospital Leuven Leuven, Belgium
  • University Hospital Ostrava Ostrava, Czechia
  • Odense University Hospital Odense, Denmark
View all 13 locations
View Trial Details

Related conditions